CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

BIVIGAM

RegulatoryapprovedBIVIGAMPositive
AI Analysis

Summary

BIVIGAM has received FDA approval for the treatment of Primary Humoral Immunodeficiency. This regulatory milestone represents approval of the biologic product for an indicated therapeutic use.

Outcome Details

Product approval indicated for treatment of Primary Humoral Immunodeficiency

Importance:7/10
Sentiment:
0.80
FDA approvalimmunodeficiencybiologics

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on July 17, 2026 3:11 PM

Read Original